REFERENCES
- Teel DW, Klein JO, Rosner B, the Greater Boston Otitis Media Study Group. Epidemiology of otitis media during the first seven years of life in children in Greater Boston: a prospective cohort study. J Infect Dis 1989; 160: 83–94.
- Giebink GS, Canafax DM, Kempthorne J. Antimicrobial treatment of acute otitis media. J Pediatr 1991; 119: 495–500.
- Anonymous. Drugs for treatment of acute otitis media in children. Med Lett 1994; 86: 19–21.
- Kaplan SL, Mason EOJr. Antimicrobial agents: resistance patterns of common pathogens. Pediatr Infect Dis J 1994; 13: 1050–3.
- Aronovitz G. A multicentre, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996; 15: S15–9.
- Behre U, Burow H-M, Quinn P, Cree F, Harrison HE. Efficacy of twice daily dosing of amoxycillin/clavulanate in acute otitis media in children. Infection 1997; 25: 163–6.
- Hoberman A, Paradise JL, Burch DJ et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin®) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997; 16: 463–70.
- McLinn S. A multicentre, double-blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J 1996; 15: S20–3.
- Ball P, Geddes A, Rolinson G. Amoxycillin clavulanate: an assessment after 15 years of clinical application. J Chemother 1997; 9: 167–98.
- Bluestone CD, Klein JO. In: Otitis media in infants and children. 2nd ed. Philadelphia: Saunders 1995; 145.
- Cook RC, Zachariah J, Cree F, Harrison HE. Efficacy of twice-daily amoxycillin/clavulanate (Augmentin® Duo 400/57) in mild-to-moderate lower respiratory tract infection in children. Br J Clin Pract 1996; 50: 125-8.
- Calver AD, Walsh NS, Quinn PF et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24: 570–4.
- Cooper CE, Slocombe B, White AR. Effect of low con-centrations of clavulanic acid on the in vitro activity of amoxi-cillin against beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 1990; 26: 371–80.
- Thorburn CE, Molesworth SJ, Sutherland E, Rittenhouse S. Postantibiotic and post beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob Agents Chemother 1996; 40: 2796–801.
- Wilson WR. Tolerance and safety of orally administered antimicrobial agents: an important factor in the selection of drug therapy. Curr Ther Res Clin Exp 1994; 55 ( Suppl A): 49-56.
- Bottenfield GW, Burch DJ, Hedrick JA, Schaten R, Rowinski CA, Davies JT. Safety and tolerability of a new for-mulation (90 mg/kg/day divided every 12 hours) of amoxi-cillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998; 17: 963–8.
- Grob PR. Antibiotic prescribing practices and patient compliance in the community. Scand J Infect Dis 1992; 83: 7–14.
- Urquhart J. Ascertaining how much compliance is enough with out-patient antibiotic regimens. Postgrad Med J 1992; 68 (suppl 3): S49-58.